Trevi Therapeutics Stock Buy Hold or Sell Recommendation
| TRVI Stock | USD 2.91 0.18 6.59% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Trevi Therapeutics is 'Strong Sell'. The recommendation algorithm takes into account all of Trevi Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Trevi Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide. In addition, we conduct extensive research on individual companies such as Trevi and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Trevi Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Trevi |
Execute Trevi Therapeutics Buy or Sell Advice
The Trevi recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Trevi Therapeutics. Macroaxis does not own or have any residual interests in Trevi Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Trevi Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Trevi Therapeutics Trading Alerts and Improvement Suggestions
| Trevi Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (29.07 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Trevi Therapeutics currently holds about 77.86 M in cash with (31.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82. | |
| Trevi Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 81.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference |
Trevi Therapeutics Returns Distribution Density
The distribution of Trevi Therapeutics' historical returns is an attempt to chart the uncertainty of Trevi Therapeutics' future price movements. The chart of the probability distribution of Trevi Therapeutics daily returns describes the distribution of returns around its average expected value. We use Trevi Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Trevi Therapeutics returns is essential to provide solid investment advice for Trevi Therapeutics.
| Mean Return | 0.03 | Value At Risk | -6.01 | Potential Upside | 7.37 | Standard Deviation | 3.97 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Trevi Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Trevi Stock Institutional Investors
| Shares | Mccormack Advisors International | 2024-06-30 | 1.3 M | Geode Capital Management, Llc | 2024-06-30 | 1.1 M | State Street Corp | 2024-06-30 | 899.9 K | Silverarc Capital Management, Llc | 2024-06-30 | 844.2 K | Rosalind Advisors, Inc. | 2024-09-30 | 750 K | Landscape Capital Management,llc | 2024-06-30 | 605.4 K | Northern Trust Corp | 2024-09-30 | 433.6 K | Tejara Capital Ltd | 2024-06-30 | 406 K | Longwood Capital Partners Llc | 2024-09-30 | 290.5 K | Nea Management Company, Llc | 2024-06-30 | 11.4 M | Logos Global Management Lp | 2024-06-30 | 5.6 M |
Trevi Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Trevi Therapeutics or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Trevi Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Trevi stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.15 | |
β | Beta against Dow Jones | 1.79 | |
σ | Overall volatility | 3.97 | |
Ir | Information ratio | -0.02 |
Trevi Therapeutics Volatility Alert
Trevi Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Trevi Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Trevi Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Trevi Therapeutics Fundamentals Vs Peers
Comparing Trevi Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Trevi Therapeutics' direct or indirect competition across all of the common fundamentals between Trevi Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Trevi Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Trevi Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Trevi Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Trevi Therapeutics to competition |
| Fundamentals | Trevi Therapeutics | Peer Average |
| Return On Equity | -0.6 | -0.31 |
| Return On Asset | -0.37 | -0.14 |
| Current Valuation | 148.54 M | 16.62 B |
| Shares Outstanding | 76.87 M | 571.82 M |
| Shares Owned By Insiders | 1.18 % | 10.09 % |
| Shares Owned By Institutions | 80.60 % | 39.21 % |
| Number Of Shares Shorted | 1.72 M | 4.71 M |
| Price To Book | 3.61 X | 9.51 X |
| EBITDA | (33.8 M) | 3.9 B |
| Net Income | (29.07 M) | 570.98 M |
| Cash And Equivalents | 77.86 M | 2.7 B |
| Cash Per Share | 1.82 X | 5.01 X |
| Total Debt | 1.34 M | 5.32 B |
| Debt To Equity | 0.21 % | 48.70 % |
| Current Ratio | 5.18 X | 2.16 X |
| Book Value Per Share | 0.78 X | 1.93 K |
| Cash Flow From Operations | (31.71 M) | 971.22 M |
| Short Ratio | 3.78 X | 4.00 X |
| Earnings Per Share | (0.44) X | 3.12 X |
| Target Price | 9.11 | |
| Number Of Employees | 27 | 18.84 K |
| Beta | 1.01 | -0.15 |
| Market Capitalization | 209.84 M | 19.03 B |
| Total Asset | 89.4 M | 29.47 B |
| Retained Earnings | (239.13 M) | 9.33 B |
| Working Capital | 81.72 M | 1.48 B |
| Net Asset | 89.4 M |
Note: Disposition of 1840 shares by Jennifer Good of Trevi Therapeutics at 1.43 subject to Rule 16b-3 [view details]
Trevi Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Trevi . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Trevi Therapeutics Buy or Sell Advice
When is the right time to buy or sell Trevi Therapeutics? Buying financial instruments such as Trevi Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Trevi Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Energy ETFs Thematic Idea Now
Energy ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Energy ETFs theme has 92 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Energy ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trevi Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trevi Therapeutics. If investors know Trevi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trevi Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Return On Assets (0.37) | Return On Equity (0.60) |
The market value of Trevi Therapeutics is measured differently than its book value, which is the value of Trevi that is recorded on the company's balance sheet. Investors also form their own opinion of Trevi Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Trevi Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trevi Therapeutics' market value can be influenced by many factors that don't directly affect Trevi Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trevi Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Trevi Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trevi Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.